stoxline Quote Chart Rank Option Currency Glossary
  
Clene Inc. (CLNN)
3.82  -0.08 (-2.05%)    07-18 16:00
Open: 3.95
High: 3.9799
Volume: 31,122
  
Pre. Close: 3.9
Low: 3.71
Market Cap: 34(M)
Technical analysis
2025-07-18 4:40:04 PM
Short term     
Mid term     
Targets 6-month :  4.9 1-year :  5.39
Resists First :  4.2 Second :  4.61
Pivot price 3.81
Supports First :  3.52 Second :  2.93
MAs MA(5) :  3.78 MA(20) :  3.88
MA(100) :  3.55 MA(250) :  4.42
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  49.1 D(3) :  38.9
RSI RSI(14): 50.4
52-week High :  6.96 Low :  2.27
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ CLNN ] has closed below upper band by 48.0%. Bollinger Bands are 66.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.98 - 4.01 4.01 - 4.02
Low: 3.66 - 3.69 3.69 - 3.7
Close: 3.78 - 3.82 3.82 - 3.85
Company Description

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Headline News

Tue, 08 Jul 2025
Clene (NASDAQ: CLNN) to Conduct Neurofilament Biomarker Analysis for CNM-Au8(R) in ALS in Early Q4 2025 - The Globe and Mail

Mon, 30 Jun 2025
Clene (NASDAQ: CLNN) Advances Regulatory Strategy for CNM-Au8 with FDA Meetings Scheduled for ALS and MS Programs - The Globe and Mail

Mon, 30 Jun 2025
FDA Shows Support for Clene ALS Drug: Biomarker Plan Advances, NDA Filing Expected Late 2025 - Stock Titan

Thu, 08 May 2025
Clene Inc. Advances CNM-Au8 Treatment for ALS, Reports Promising Q1 Results - citybuzz -

Tue, 06 May 2025
Clene Faces Nasdaq Delisting Risk Amid Regulatory Pursuits - TipRanks

Mon, 14 Apr 2025
Clene to Present at the Emerging Growth Conference - TradingView

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 9 (M)
Held by Insiders 6.14e+006 (%)
Held by Institutions 34.5 (%)
Shares Short 170 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.631e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -5 %
Return on Assets (ttm) 32 %
Return on Equity (ttm) -49.7 %
Qtrly Rev. Growth 350000 %
Gross Profit (p.s.) 22.91
Sales Per Share 0
EBITDA (p.s.) 575000
Qtrly Earnings Growth -4.1 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -19 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -3.22
Stock Dividends
Dividend 0
Forward Dividend 355530
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android